A securities class action has been filed against Zenas BioPharma, Inc. (ZBIO) on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company’s September 13, 2024 initial public offering (“IPO”). This case has been filed in the USDC – MA.
The Complaint alleges that the Registration Statement issued in connection with the Company’s initial public offering (the “IPO” or “Offering”) contained false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, Defendants public statements were materially false and misleading at all relevant times and negligently prepared.